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SUMMARY
AMPK is a sensor of cellular energy status and a
promising target for drugs aimed at metabolic disor-
ders.We have studied the selectivity andmechanism
of a recently described activator, C2, and its cell-
permeable prodrug, C13. C2 was a potent allosteric
activator of a1-complexes that, like AMP, also pro-
tected against Thr172 dephosphorylation. Compared
with AMP, C2 caused only partial allosteric activation
of a2-complexes and failed to protect them against
dephosphorylation. We show that both effects could
be fully restored by exchanging part of the linker be-
tween the autoinhibitory and C-terminal domains in
a2, containing the equivalent region from a1 thought
to interact with AMP bound in site 3 of the g subunit.
Consistent with our results in cell-free assays, C13
potently inhibited lipid synthesis in hepatocytes
from wild-type and was largely ineffective in AMPK-
knockout hepatocytes; its effectsweremore severely
affected by knockout of a1 than of a2, b1, or b2.
INTRODUCTION
AMP-activated protein kinase (AMPK) is a central energy sensor
and regulator of energy homeostasis (Hardie et al., 2012; Stein-
berg and Kemp, 2009). AMPK is activated by metabolic stresses
that lower cellular energy status by decreasing the catabolic
generation of ATP or by accelerating ATP consumption. Upon
activation, it functions to restore cellular energy homeostasis by
switching off anabolic pathways and other ATP-consuming pro-
cesses while switching on ATP-producing catabolic pathways.
AMPK is a heterotrimer composed of a catalytic a subunit and
regulatory b and g subunits. Multiple genes encoding isoforms
(a1, a2; b1, b2; g1, g2, g3) as well as transcriptional variants exist
for each of the subunits, generating at least 12 distinct heterotri-
meric complexes (Hardie et al., 2012; Steinberg and Kemp,
2009). There are cell- and tissue-specific expressions of some
isoforms, and they may also target AMPK complexes to specific
subcellular locations (Hudson et al., 2003; Salt et al., 1998). The g
subunits contain four tandem cystathionine b-synthase (CBS)
repeats that provide four potential sites for adenine nucleotide
binding, although only three are used (Xiao et al., 2007). AMPK
activity increases >100-fold on phosphorylation of a conserved
threonine residue within the activation loop (Thr172 in rat a2;
Hawley et al., 1996). Binding of ADP and/or AMP causes confor-
mational changes that promote net Thr172 phosphorylation by
(1) the promotion of Thr172 phosphorylation and (2) the inhibition
of Thr172 dephosphorylation (Gowans et al., 2013; Oakhill et al.,
2011; Xiao et al., 2011). In addition, the binding of AMP (but not
ADP) further stimulates AMPK activity by >10-fold by allosteric
activation (Gowans et al., 2013). The major upstream kinase
phosphorylating Thr172 in most mammalian cells is a complex
containing the tumor suppressor kinase LKB1, which appears
to be constitutively active (Alessi et al., 2006; Sakamoto et al.,
2004). In some cells, Thr172 can be phosphorylated in a Ca2+-
mediated process catalyzed by Ca2+/calmodulin-dependent
protein kinase kinases (Hardie et al., 2012; Steinberg and
Kemp, 2009).
AMPK is considered a major target for drugs to combat the
growing epidemic of metabolic disorders (Hardie et al., 2012)
because AMPK activation elicits metabolic responses expected
to counteract the physiological or metabolic abnormalities asso-
ciated with obesity, insulin resistance, and type 2 diabetes. For
example, AMPK phosphorylates and inactivates acetyl-CoA
carboxylase-1 (ACC1) and HMG-CoA reductase, key enzymes
of fatty acid and sterol biosynthesis, respectively (Hardie et al.,
2012; Steinberg and Kemp, 2009). Moreover, numerous studies
have demonstrated that the activation of AMPK leads to
increased fatty acid oxidation through phosphorylation of
866 Chemistry & Biology 21, 866–879, July 17, 2014 ª2014 The Authors
acetyl-CoA carboxylase-2 (ACC2) (Merrill et al., 1997) and
glucose uptake in skeletal muscle involving phosphorylation of
TBC1D1 (O’Neill et al., 2011; Pehmøller et al., 2009; Sakamoto
and Holman, 2008), whereas AMPK signaling to ACC is required
for the lipid-lowering and insulin-sensitizing effects of metformin
(Fullerton et al., 2013). In line with this, 5-aminoimidazole-4-car-
boxamide riboside (AICAR), the most widely used pharmacolog-
ical AMPK activator, which is converted within cells to the
AMP-mimetic AICAR monophosphate (ZMP), improved insulin
sensitivity in animal models of insulin resistance (Hardie et al.,
2012). However, ZMP modulates other AMP-sensitive enzymes
of carbohydrate metabolism, including fructose-1,6-bisphos-
phatase in the liver (Vincent et al., 1991) and glycogen phos-
phorylase in muscle (Longnus et al., 2003). In fact, some
metabolic effects of AICAR have been shown to be AMPK-
independent (Foretz et al., 2010; Guigas et al., 2009). Cool
et al. (2006) described the identification of the thienopyridone
A769662, the first small-molecule direct activator of AMPK.
A769662, like AMP, inhibits Thr172 dephosphorylation (Go¨rans-
son et al., 2007; Sanders et al., 2007). However, this does not
appear to be its primarymechanism of AMPK activation because
A769662 can allosterically activate AMPK in the absence of
Thr172 phosphorylation, either alone or in the presence of
AMP, depending on the phosphorylation state of Ser108 on the
b1 subunit (Scott et al., 2014a). The strong synergy between
AMPandA769662 in allosteric activation of AMPK in cell-free as-
says (Scott et al., 2014a) is also observed in vivo (Ducommun
et al., 2014; Foretz et al., 2010; Timmermans et al., 2014).
A769662 binds to a site located between the a subunit kinase
domain and the b subunit carbohydrate-binding module, which
is distinct from the adenine nucleotide-binding sites on the
g subunit (Xiao et al., 2013). A769662 is rather selective for
complexes containing b1 rather than the b2 isoform (Scott
et al., 2008). The small-molecule AMPK activator 991 was
also shown to bind at the A769662 site (Xiao et al., 2013). We
recently reported that salicylate is a direct activator of AMPK
and that it binds the same site as A769662 (Hawley et al.,
2012). These studies demonstrate that various small molecules
can stimulate AMPK activity through different binding sites and
mechanisms.
Recently, Go´mez-Galeno et al. (2010) screened a library of
1,200 AMP mimetics and identified 5-(5-hydroxyl-isoxazol-3-
yl)-furan-2-phosphonic acid (compound 2, C2) as a potent
allosteric activator of AMPK. They also showed that a prodrug
(compound 13, C13), stimulated AMPK and inhibited hepatic
lipogenesis in vivo. However, the study provided little information
about the molecular actions of C2 or C13 on AMPK or about its
specificity and biological effects in intact cells. We have investi-
gated the effects of C2 on various combinations of recombinant
abg complexes in cell-free assays and the effects of C13 in pri-
mary hepatocytes from wild-type (WT) and AMPK-isoform-spe-
cific-knockout mice in order to gain insights into its mechanism
of action and overall effects on lipid metabolism. We report
that C2 is a potent allosteric activator of a1 complexes that,
like the natural activator AMP, also protects against Thr172
dephosphorylation. Unexpectedly, but of significance, C2 is
rather selective for a1 complexes in cell-free assays and its
cell-permeable prodrug C13 is also a selective activator of a1
complexes in intact cells.
RESULTS
Effects of AMP and C2 on Recombinant AMPK
Complexes in Cell-Free Assays
The structure of the endogenous activator of AMPK, AMP, is
shown in Figure 1A along with C2, 991, salicylate, and the
classical AMPK tool compound, ZMP, which is generated by
phosphorylation by cellular enzymes of the prodrug, AICAR. C2
bears close structural similarity to AMP, with an acidic 5-hydrox-
yisoxazole group in place of adenine. It is structurally distinct
from the prototypical non-nucleotide AMPK activator, A769662
(Figure 1A). However, in common with ZMP, the charged nature
of C2 results in poor membrane permeability, and it is adminis-
tered in cell-based and in vivo analyses in the form of an
esterase-sensitive phosphonate prodrug, C13 (Figure 1A). C2
was reported to activate human AMPK with half-maximal effec-
tive concentration (EC50) at 6.3 nM, but the exact isoform combi-
nation used and whether it was purified from bacteria, insect, or
mammalian cells were not specified (Go´mez-Galeno et al., 2010).
We initially compared the ability of C2 and AMP to activate
various recombinant human AMPK complexes, expressed in in-
sect cells, in cell-free assays (Figure 1B). As reported previously
using rat liver complexes separated by immunoprecipitation
(Salt et al., 1998), the allosteric activation of a1 complexes by
AMPwas less than that of a2 complexes. Despite this difference,
C2 and AMP were equally effective in allosteric activation of the
major a1-containing complexes (a1b1g1, a1b2g1, and a1b1g2),
although C2 was two orders of magnitude more potent than
AMP, with an EC50 of 10–30 nM, compared to 2–4 mM for
AMP. Unexpectedly, C2 was only a partial agonist of a2-contain-
ing complexes compared with AMP, exhibiting only 15% of the
maximal response to saturating AMP using the a2b1g1 complex.
Similar results were obtained with other permutations of b and g
subunits in complex with a2 (data not shown). We also tested the
effects of C2 and AMP on recombinant human a1b1g1 and
a2b1g1 complexes expressed in E. coli and obtained similar re-
sults (data not shown). The small, partial activation of the a2b1g1
complex was also potent (EC50 of 15 nM, compared to 3 mM for
AMP). Characterization of the subunit composition of the recom-
binant complexes used in this study is shown in Fig-
ure S1(available online).
Effects of C2 on Other AMP-Regulated Enzymes and
Protein Kinases
AMP (and ZMP) are known to allosterically modulate several
enzymes other than AMPK; for example, AMP activates 6-phos-
phofructo-1 kinase (PFK1), and AMP and ZMP inhibit the
gluconeogenic enzyme fructose-1,6-bisphosphatase-1 (FBP1)
(Vincent et al., 1991). As expected, AMP activated PFK1 with
an EC50 of 33 mM and inhibited FBP1 with a half-maximal inhib-
itory concentration (IC50) of 5 mM (Figure 1C). By contrast, C2 had
no effect on PFK1 and FBP1 at concentrations up to 100 mM
(Figure 1C), nor did it antagonize the effects of AMP on these
enzymes (data not shown). Moreover, we have tested the effect
of C2 on another AMP-regulated enzyme (muscle glycogen
phosphorylase b) and enzymes using AMP as substrate (AMP
deaminase-1, adenylate kinase, and 50-nucleotidase). None of
these enzymes were affected by C2 at concentrations up to
100 mM (data not shown).
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To determine whether C2 affects the activity of any other pro-
tein kinases, we screened it in cell-free assays against a panel
of 138 protein kinases. The majority were not affected by
10 mM C2 (Figure S2), including several that are members of
the AMPK-related kinase family (SIK2, SIK3, NUAK1, MELK,
MARK1, MARK2, MARK3, MARK4, BRSK1, and BRSK2). More-
over, C2 did not affect any of the known upstream kinases of
AMPK, including LKB1, CaMKKb, and TAK1 (Figure S2). A few
kinases were marginally inhibited by C2 at 10 mM, which is
z10-fold higher than the concentration that is saturating for
AMPK activation in cell-free assays (Figure 1B). Taken together,
these results suggest that C2 is a rather specific AMPK activator.
C2 Is a Partial Agonist of AMPKa2 Complexes and Does
Not Protect Their Activation Loops from
Dephosphorylation
Speculating that C2 exerts its effects by exploiting the same
binding site on the g subunits as AMP, we found themodest allo-
steric activation of a2 complexes by C2 compared to AMP unex-
pected. One explanation is the presence of a second, inhibitory
site unique to a2. Indeed, at the low concentrations of ATP typi-
cally used in radiometric kinase assays, activation by AMP itself
is biphasic, with a pronounced inhibitory effect at high concen-
trations due to competition with ATP at the catalytic site (Gowans
et al., 2013). However, C2 had no effect on the activity of iso-
lated, full-length a subunits when assayed under identical condi-
tions to Figure 1B (Figure S3A), showing that it does not compete
with ATP at the catalytic site. Go´mez-Galeno et al. (2010)
reported that C2 activated only partially an AMPK preparation
from rat liver. Similarly, we found that C2 activated rat liver
AMPK to only half the extent that AMP did (Figure S3B), which
is probably because this preparation contains a roughly equal
mixture of a1b1g1 and a2b1g1 complexes (Woods et al.,
1996). In addition, C2 antagonized activation by AMP, reducing
the activity of rat liver AMPK stimulated by 30 mM AMP by
z50%, as expected for a partial agonist (Figure S3C). This
was confirmed using isolated a1b1g1 and a2b1g1 complexes
(Figures 2A and 2B); increasing concentrations of C2 had no
effect on the activity of an a1b1g1 complex measured in the
presence of 30 mM AMP, but it reduced the activity of an
a2b1g1 complex toz15% above basal (similar to the maximum
effect of C2 alone on this complex; Figure 1B). These results sup-
port the assumption that C2 and AMP share at least one mutual
binding site or transduction mechanism. Consistent with this,
activation of a1b1g1 by C2 was antagonized by ADP (Fig-
ure S3D), which also binds to the g subunit but does not elicit
an allosteric response and behaves as a competitive antagonist
under these conditions (Xiao et al., 2011). We also observed
that C2 failed to stimulate an AMPK complex containing a point
mutation in the g2 subunit (R531G), which renders AMPK
complexes insensitive to AMP (Sanders et al., 2007), whereas
activation by C2 was unaffected on AMPK containing a carbohy-
drate-binding-domain (CBD)-deletion mutant in the b1 subunit
(b1 D1–185, which renders AMPK complexes insensitive to
A769662; Sanders et al., 2007; Scott et al., 2008) (Figure 2E).
Moreover, C2 and AMP displaced a GST-AMPKg2 subunit
fusion from ATP-g-Sepharose to the same extent, indicating
that both ligands compete for the same site(s) as ATP on the
isolated g2 subunit (Figure S3E).
In addition to allosterically activating AMPK (a key part of the
overall activationmechanism;Gowans et al., 2013), AMPbinding
also promotes an increase in Thr172 phosphorylation, mainly by
protecting the complex against dephosphorylation by protein
phosphatases. To test whether binding of C2, like AMP, inhibited
the dephosphorylation of Thr172, the a1b1g1 complex was incu-
bated with protein phosphatase PP2Ca in the presence or
absence of AMP or C2. As expected, AMP provided partial pro-
tection against Thr172 dephosphorylation, and we now show
that C2 also afforded partial protection at 1 mM (Figure 2C). Inter-
estingly, C2 had essentially no effect on the dephosphorylation
of an a2b1g1 complex (Figure 2D) at concentrations (1–10 mM)
where the previously observed modest allosteric activation
(see Figure 1B) was maximal. As expected, C2 was only partially
effective when similar assays were performed using the rat liver
preparation (data not shown). We also verified that these con-
centrations of C2 had no direct effect on PP2Ca activity, assayed
using a synthetic peptide substrate corresponding to the T loop
sequence of AMPKa1/a2. The plant alkaloid sanguinarine was
recently reported to be a PP2C inhibitor (Aburai et al., 2010)
and was included as a positive control (Figure S3F).
C2 Can Be Rendered a Full Agonist of a2 Complexes by
Substitution of Regulatory Elements from a1
The data shown in Figure 2E and Figure S3E suggest that C2
functions through binding to the g subunit and that the poor
response of a2 versus a1 complexes to the compound (relative
to AMP) may be due to the different sequences of a1 and a2 iso-
forms in the region that contacts the AMP-binding domains of
the g subunit. Structures of active heterotrimeric complexes
containing a1 or a2 (Xiao et al., 2011, 2013) revealed that the
a linker, which connects the autoinhibitory and C-terminal do-
mains (a-AID and CTD) of the a subunit, wraps around one
face of the g subunit, contacting AMP bound in site 3. In the orig-
inal model (Xiao et al., 2011), a region termed the a hook (a1 384–
393, Figure 3A and Figure S4) was proposed to contact AMP
bound in site 3 (Xiao et al., 2011). While our study was in prog-
ress, this model was revised and the sequence corresponding
to the a hook was reassigned (also referred to as a-RIM2)
Figure 1. The AMP Analog C2 Is a Potent AMPK Activator in Cell-Free Assays with Selectivity for a1 Complexes
(A) The structure of the endogenous activator of AMPK, AMP; the AMPmimetic, C2; and the classical AMPmimetic, ZMP, and other AMPK activators are shown.
C2 and ZMP exhibit poor membrane permeability and are administered as the prodrugs, C13 and AICAR, respectively.
(B) Recombinant AMPK complexes (a1b1g1, a2b1g1, a1b1g2, and a1b2g1) expressed inSpodoptera frugiperdawere assayed for allosteric activation by AMP or
C2. Results are expressed as the increase in activity relative to controls without ligand and represent the mean ± SD for three independent experiments.
(C) Enzymes allosterically regulated by AMP (PFK1 and FBP1) or using AMP as a substrate (AMPD1, AK, and 50-NT) were assayed in the presence of C2
(% 100 mM). Enzymes allosterically regulated by AMPwere screened for both agonism and antagonism, the latter in the presence of AMP atz EC50. All enzymes
were unaffected by [C2]% 100 mM. Representative data are shown for the effects of AMP and C2 on PFK1 and FBP1 activity. Results are representative of three
independent experiments conducted on one enzyme preparation.
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(Chen et al., 2013; Xiao et al., 2013), as discussed in more detail
in the Discussion section. However, the original model was used
to guide the experiments described in the next paragraph.
To identify the region that determines the isoform specificity of
C2, we designed and prepared a series of recombinant com-
plexes with chimeric a subunits comprising combinations
of the catalytic and regulatory elements (Figure 3A; Figure S4).
The substitution of a2b1g1 with the catalytic domain from a1
(a2/a1 CAT) had no significant impact on the ability of C2 to allo-
sterically activate AMPK (Figure 3B, top) or protect against
dephosphorylation by PP2Ca (Figure 3B, bottom), confirming
that the poor activation of a2 complexes by C2 is not because
it antagonizes ATP binding at the catalytic site. However, when
the region of a2 C-terminal to the kinase domain was replaced
with the complementary region from a1 (a2/a1 REG), the com-
plex was fully activated by C2 with an EC50 comparable to
a1b1g1 (Figure 3C, top) and was as effective as AMP at protect-
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Figure 2. C2 Is a Partial Agonist of a2 Com-
plexes and Selectively Protects a1 Com-
plexes against Dephosphorylation by PP2C
(A and B) Recombinant AMPKa1b1g1 (A) or
AMPKa2b1g1 (B) was assayed in the presence of
AMP (30 mM) and increasing concentrations of C2
(0–20 mM). Results are expressed as fold increase
in activity relative to controls without ligand and
represent the mean ± SD for three independent
experiments.
(C and D) The effects of C2 and AMP on dephos-
phorylation and inactivation of AMPKa1b1g1 (C)
and a2b1g1 (D) by PP2Ca (present in all assay
conditions). Results are expressed as a percent-
age of control reactions performed in the absence
of Mg2+ and represent the mean ± SD of three in-
dependent experiments. Representative blots of
pT172 and total AMPKa are shown below the bar
charts.
(E) AMPKa1b1g2 WT (open bars) and mutant
complexes (b1 DCBD [b1 D1–185], gray bars, and
g2 R531G, black bars) were purified from COS1
cells by transient overexpression of the indicated
constructs, as described in Methods, and assayed
in the presence of the indicated compounds under
standard conditions. Results are expressed as the
fold increase in activity relative to controls in the
absence of compound and represent the mean ±
SD for three independent experiments. The right-
hand panel shows an analysis of the subunit
composition of the preparations by western blot-
ting with the indicated antibodies.
ing against dephosphorylation (Figure 3C,
bottom). When we limited the substitution
of the C-terminal region of a2 to the a
hook of a1 (a2/a1 HOOK), the rescue
was lost, with no discernible impact on
either allosteric activation or protection
against dephosphorylation (Figure 3D).
However, a full rescue could be realized
by substituting the full region of low simi-
larity between a1 and a2, (a2/a1 LOOP,
which includes both the a-RIM2 and a
hook sequences) (Figure 3E). This yielded results essentially
identical to substituting the entire C-terminal region (Figure 3C).
These results were confirmed in intact cells by the transient over-
expression of FLAG-a2, b1, and g1 in COS1 cells treated with the
C2 prodrug, C13 (Figure S4B). Cells expressing WT FLAG-a2
were unresponsive up to 100 mM C13, whereas FLAG-a2/a1
LOOP complexes were activated by C13 treatment to a similar
extent as AICAR (used in combination with methotrexate to in-
crease ZMP accumulation). These results highlight a hitherto un-
revealed difference between the regulatory apparatus of a1 and
a2 complexes, and indicate the potential for exploiting these dif-
ferences to design isoform-selective AMPK activators.
Effects of the C2 Prodrug (C13) on AMPK Signaling in
Primary Mouse Hepatocytes
Previous studies have shown that C2 displayed no signifi-
cant cellular accumulation in primary hepatocytes when used
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at 100 mM for up to 6 hr (Go´mez-Galeno et al., 2010), sug-
gesting that it has poor cell permeability, perhaps due to
its anionic nature. Go´mez-Galeno et al. (2010) synthesized a
series of prodrugs in which the phosphate moiety was deri-
vatized using esterase-sensitive groups. Among these, C13
(Figure 1A) displayed the most potent inhibition of whole-
body lipogenesis in mice, and thus we chose it for our cell-
based studies.
When mouse primary hepatocytes were incubated with
various concentrations of C13 for 1 hr, we observed
a modest elevation of Thr172 phosphorylation at concentra-
tions as low as 10 mM and a concentration-dependent increase
up to 100 mM (Figure 4A). Thr172 phosphorylation at 100 mM
was lower than with 0.5 mM AICAR. Phosphorylation of ACC,
a marker for AMPK activation, was evident at concentrations
above 0.03–0.1 mM and appeared to be saturated at 1–3 mM.
By contrast, other AMPK substrates (i.e., Raptor and ULK1)
were significantly phosphorylated only at concentrations above
1–3 mM. Because AMPK is thought to inhibit the mammalian
target of rapamycin complex 1 (mTORC1) pathway via the
phosphorylation of Raptor and TSC2 (Hardie et al., 2012), we
also assessed the phosphorylation of Thr389 on p70S6K1, a
marker for mTORC1 activation. We observed that Thr389
phosphorylation was suppressed at concentrations >1 mM,
correlating inversely with Raptor phosphorylation (Figure 4A).
We also found that C13 suppressed insulin-stimulated
mTORC1 activation, as judged by phosphorylation of p70S6K
and 4EBP1 (Figure S5).
Given that C2 more effectively activated recombinant a1 than
a2 complexes in cell-free assays, wewished to examine whether
it would also preferentially activate a1 complexes in intact cells.
Indeed, C13 stimulated a1 complexes in primary hepatocytes at
much lower concentrations (3 mM) than a2 complexes, whose
activation was evident only at concentrations above 30 mM (Fig-
ure 4B). Note that in these assays, which were conducted in
washed immunoprecipitates made using isoform-specific anti-
bodies, any allosteric activation by C2 or by endogenous AMP
would be lost, so the activity is a reflection only of increased
Thr172 phosphorylation. A time course at saturating C13
(30 mM) revealed that Thr172 phosphorylation continually
increased up to 2 hr, whereas the phosphorylation of down-
stream targets (ACC, Raptor, and ULK1) was maximal within
45–60 min (Figure 4C).
We next sought to explore the mode of action of C13 in stim-
ulating AMPK. We first assessed ADP:ATP and AMP:ATP ra-
tios. As expected, 2,4-dinitrophenol (DNP) and H2O2 increased
these ratios (Figure 4D), but there were no detectable changes
when hepatocytes were incubated with C13 at concentra-
tions up to 100 mM for 1 hr. Activation of AMPK requires
Thr172 phosphorylation, and this is primarily mediated by
LKB1 or CaMKKb. We first examined the requirement for
CaMKKb using the relatively selective CaMKK inhibitor, STO-
609. Ionomycin, which activates AMPK via increased intracel-
lular [Ca2+] and activation of CaMKKb, was used as a positive
control. Prior incubation of hepatocytes with STO-609 almost
completely abolished the phosphorylation of AMPK and ACC
by ionomycin, but not C13 (Figure 4E). We next measured
C13-stimulated AMPK phosphorylation in WT and LKB1/
mouse embryonic fibroblasts. Both AICAR- and C13-induced
phosphorylation of AMPK and ACC were abolished in LKB1/
cells (Figure 4F).
C13 Inhibits Lipogenesis and Fatty Acid Esterification
One of the best-characterized physiological consequences of
AMPK activation is the suppression of hepatic fatty acid and
sterol synthesis by phosphorylation of the classical substrates,
ACC and HMG-CoA reductase. Primary mouse hepatocytes
were incubated with C13, and [14C]acetate incorporation into
saponifiable lipid (fatty acids) and nonsaponifiable lipids (princi-
pally sterols) was assessed. There was a concentration-depen-
dent inhibition of lipid synthesis in response to C13 (IC50 of
1.7 mM for saponifiable lipids and 1.5 mM for nonsaponifiable
lipids), with a maximal effect at 30 mM (Figure 5A). Based on
a similar degree of inhibition with 3 mM C13 and 100 mM
A769662 (Figure 5A), C13 appeared to bez30-fold more potent
than A769662. We also measured the effect of C13 on fatty acid
esterification by assessing [3H]palmitic acid incorporation into
triglycerides. C13 inhibited fatty acid esterification (Figure 5B),
as previously observed in rat hepatocytes using AICAR (Muoio
et al., 1999).
AMPK Is Required for Inhibition of Lipid Synthesis
by C13
To confirm that inhibition of lipid synthesis by C13 is mediated
by AMPK, we isolated primary hepatocytes from liver-specific
AMPKa1/ -a2/ (AMPK-knockout, AMPK-KO) mice or WT
controls. C13 dose-dependently inhibited the synthesis of
saponifiable and nonsaponifiable lipids in WT hepatocytes,
correlating with increases in the phosphorylation of AMPK and
ACC (Figures 5C–5E). Conversely, AMPK-KO hepatocytes
were resistant to the anti-lipogenic effects of C13, correlating
with a complete loss in AMPK activation, as assessed by the
phosphorylation of Thr172 and downstream substrates (Figures
5C–5E). Lipogenesis was, however, still modestly impaired
(z20%) at the highest concentrations of C13 in AMPK-KO
hepatocytes. We suspect that this is due to limited, off-target in-
hibition of acetate-CoA ligase by C13 (Figure S6), as previously
reported for nucleotide 50-alkylphosphates that mimic the transi-
tion state (Grayson and Westkaemper, 1988).
Given that a1-containing complexes were more sensitive to
C2 in cell-free assays (Figure 1B) and to C13 in intact cells (Fig-
ure 4B), we hypothesized that a1-null hepatocytes would be
more resistant to C13-induced inhibition of lipid synthesis. Strik-
ingly, there was a shift in concentration dependence for the
effect of C13 in a1-KO hepatocytes compared to a2-KO cells; in-
cubation with 1 mMC13 had no effect on the synthesis of sapon-
ifiable and nonsaponifiable lipids in a1-KO hepatocytes,
whereas the same concentration of C13 reduced lipid synthesis
by about 40% in WT cells (Figure 6A). By contrast, a2-KO hepa-
tocytes displayed similar sensitivity to C13 as WT cells (Fig-
ure 6A). Thr172 phosphorylation (the antibody detects both a1
and a2) was slightly lower in both a1-KO and a2-KO hepatocytes
than in WT cells (Figure 6B). Concentrations of C13 required
to promote phosphorylation of Thr172 on AMPKa2, ACC, and
Raptor in a1-KO hepatocytes were also higher than those
required in WT controls. By contrast, a2-KO hepatocytes dis-
played similar concentration dependence for C13 on the phos-
phorylation of AMPK, ACC, and Raptor as WT cells (Figure 6B).
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C D E
Figure 3. Regulatory Elements within the a-Linker Determine the Isoform Specificity of C2
(A) Diagram illustrating the domain organization of the AMPKa subunit with a global pairwise alignment of a section of the a-linker of human AMPKa1 (Q13131)
and AMPKa2 (P54646). Regulatory elements in the a-linker are highlighted, including the a-hook as originally defined by Xiao et al. (2011) (pink) and the
(legend continued on next page)
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Effect of C13 on Lipogenesis and AMPK Signaling in
AMPKb1–/– and b2–/– Hepatocytes
Finally, we examined whether C13 requires specific b subunit
isoforms to modulate lipid synthesis and AMPK signaling. As
previously described (Dzamko et al., 2010), b1 is the predomi-
nant isoform in mouse liver, and its deletion resulted in instability
and/or degradation of the a subunits, thus reducing Thr172
reassigned sequence (also known as a-RIM2) shaded in orange. The secondary structure for a1 is derived from PDB ID 2Y94. The table summarizes the
sequences of the a1/a2 chimeras produced to examine the role of various structural elements in the activation of a2b1g1 complexes by C2.
(B–E) Human AMPKa1/a2 chimeras (defined in A) were generated as complexes with b1g1 in E. coli. Purified active complexes were assayed for the activation of
phosphotransferase activity by AMP and C2, as described in Figure 1. Results (line graphs) are expressed as the fold increase in activity relative to reactions
performed in the absence of compound and represent the mean ± SD of three independent experiments. Complexes were also assayed for protection against
dephosphorylation and inactivation by PP2Ca, as described in Figures 2C and 2D. Results (bar charts) are expressed as themean (percentage of control) ± SD of
three independent experiments. Representative blots of pT172 and total AMPKa are shown below the bar charts.
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Figure 4. The C2 Prodrug, C13, Potently
Activates AMPK in Mouse Primary Hepa-
tocytes
(A) Isolated mouse hepatocytes were incubated
with vehicle or the indicated concentrations of C13
for 1 hr. AICAR (0.5mM) was included as a positive
control. Cell lysates were analyzed using western
blotting with the indicated antibodies.
(B) AMPKa1 or AMPKa2 complexes were immu-
noprecipitated from hepatocyte extracts prepared
as described in (A) and assayed for kinase activity
using 0.2 mM AMARA and 0.1 mM ATP. Results
are expressed as the mean Pi incorporated in
picomoles per minute-milligram ± SD.
(C) Hepatocytes were stimulated with 30 mM C13
for the indicated times prior to harvesting, with
AICAR (0.5 mM, 1 hr) as positive control. Lysates
were analyzed using western blotting with the
indicated antibodies.
(D) Mouse hepatocytes were treated with the
indicated compounds for 1 hr, and adenine
nucleotide ratios were determined using capillary
electrophoresis of perchloric acid extracts.
(E) Mouse hepatocytes were preincubated with
30 mMSTO-609 for 30 min prior to stimulation with
30 mM C13 for 1 hr or with 1 mM ionomycin for
30 min. Lysates were analyzed using western
blotting with the indicated antibodies.
(F) Wild-type (LKB1+/+) or LKB1-null (LKB1/)
mouse embryonic fibroblasts were incubated
with the indicated concentrations of C13 for 1 hr.
AICAR (2 mM) was included as a positive control.
Lysates were analyzed using western blotting with
the indicated antibodies. Results are representa-
tive of three independent experiments.
phosphorylation (although there was
some compensatory upregulation of b2)
(Figure 7A). By contrast, b2 deletion did
not cause a significant reduction in total
AMPKa protein or Thr172 phosphoryla-
tion (Figure 7A). C13 and A769662
robustly stimulated the phosphorylation
of Thr172 and ACC, as well as Raptor,
in WT and b2-KO hepatocytes. In b1-KO
hepatocytes, C13 modestly stimulated
Thr172 phosphorylation, which was sufficient to saturate ACC
phosphorylation, although Raptor phosphorylation was only
modestly increased. As previously reported (Fullerton et al.,
2013; Hawley et al., 2012; Scott et al., 2008), A769662 failed to
stimulate AMPK and phosphorylation of ACC and Raptor in b1-
KO hepatocytes (Figure 7A). C13 inhibited lipid synthesis to a
similar extent in hepatocytes from all genotypes at both at 30
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and 100 mM, whereas A769662 failed to suppress lipogenesis in
b1-KO hepatocytes, reflecting the known specificity of this com-
pound for b1-containing complexes (Figure 7B).
DISCUSSION
The original identification of a small-molecule AMPK activator,
A769662, provided a key molecular tool to delineate the function
of AMPK in intact cells. A unique property of this activator is
its selectivity for AMPK complexes containing the b1 subunit,
providing researchers an opportunity to study the role of different
b subunit isoforms. However, it has limited utility when studying
AMPK function in cells or tissues expressing predominantly
b2-containing complexes. The publication of a novel activator
named C2 (Go´mez-Galeno et al., 2010) drew our attention to
the strategy of developing cell-permeable AMP mimetics. One
concern, as observed with AICAR, was the potential effect of
C2 on AMP-regulated enzymes other than AMPK (PFK1, FBP1,
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Figure 5. C13 Inhibits Lipid Synthesis and
Fatty Acid Esterification in Mouse Hepato-
cytes in an AMPK-Dependent Manner
(A) Mouse hepatocytes were treated with the
indicated concentrations of C13 and labeled with
[1-14C]acetate for 3 hr. A769662 (100 mM) and
AICAR (0.5 mM) were included as positive con-
trols. Rates of fatty acid and sterol synthesis were
estimated by incorporation into saponifiable and
nonsaponifiable lipids. Results are expressed as
the mean acetate incorporated in micromoles per
gram-hour ± SD and are representative of two
independent experiments.
(B) Mouse hepatocytes were treated with the indi-
cated compounds for 30 min and labeled with me-
dia containing 0.5mMpalmitic acid (1mCi,mmol1
[9,10-3H]palmitic acid) for an additional 60 min.
Incorporation into triglyceride was determined
as described in Experimental Procedures and re-
sults are expressed as palmitate incorporated in
micromoles per gram-hour ± SD and are repre-
sentative of three independent experiments.
(C and D) Mouse hepatocytes from WT or
AMPK-null (AMPKa1/ -a2/) mice were incu-
bated with the indicated concentrations of C13
and labeled with [1-14C]acetate for 3 hr. Rates of
fatty acid and sterol synthesis were estimated
from incorporation into saponifiable (C) and
nonsaponifiable (D) lipids. Results are expressed
as percentage WT vehicle and represent the
mean ± SD for three independent experiments.
(E) Hepatocytes were treated with the indicated
concentrations of C13 for 3 hr, and lysates were
blotted with the indicated antibodies.
and glycogen phosphorylase). However
we showed that, unlike ZMP formed
from AICAR, C2 does not affect any of
these enzymes or several enzymes that
use AMP as a substrate. In addition,
most kinases (in a panel of 138) were
not significantly affected by 10 mM C2,
including members of the AMPK-related
kinase family or any of the known upstream kinases of AMPK.
Cell-free assays of several AMPK complexes revealed that C2
is a potent allosteric activator of AMPK (EC50 of 10–30 nM),
which is >20-fold more potent than A769662 (Cool et al., 2006;
Go¨ransson et al., 2007) and more than two orders of magnitude
more potent than AMP. We also demonstrated an unexpected
preference of C2 for a1 complexes. C2 is only a partial agonist
for allosteric activation of a2 complexes compared to AMP,
and it antagonizes allosteric activation by AMP. By contrast,
AMP and C2 are equally effective in the allosteric activation of
a1 complexes, and as full agonists, do not exhibit competitive
antagonism. Moreover, binding of C2 is much more effective at
protecting against the dephosphorylation of Thr172 using a1
rather than a2 complexes, whereas AMP is effective with both
isoforms.
C13, a prodrug of C2, activated AMPK in a concentration-
dependent manner in isolated mouse hepatocytes (which ex-
press both a1 and a2) and inhibited de novo lipid synthesis
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and fatty acid esterification, effects (at least lipid synthesis) that
were abolished in AMPK-KO hepatocytes. C13 was more effec-
tive than A769662, which was evident from the inability of
A769662 to stimulate robust phosphorylation of Raptor, which
in our experience requires a higher threshold of AMPK activity
than ACC phosphorylation. We found no change in adenine
nucleotide levels during treatment with C13 at concentrations
up to 100 mM in primary hepatocytes, showing that the com-
pound does not act indirectly via that mechanism. Furthermore,
the preference for a1 was confirmed in intact cells by the poor
activation of a2 complexes revealed by isoform-specific immu-
noprecipitation. This was also demonstrated by the marked in-
crease in IC50 for the inhibition of de novo lipogenesis in a1-KO
compared to WT hepatocytes, whereas a2 deletion was without
significant effect. Similar experiments with b1 or b2 complexes
and b1- or b2-KO hepatocytes confirmed that C13 has no pref-
erence for b subunit isoforms, either in cell-free assays or in
intact cells.
Although we have not identified the precise binding sites used
by C2, it is structurally analogous to AMP and is also equally
effective with AMP in displacing a GST-g2 fusion protein from
ATP-Sepharose. Moreover, C2 failed to activate AMPK contain-
ing a mutant g2 subunit (R531G), which renders AMPK com-
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Figure 6. C13 Is Relatively Selective for a1
Complexes in Primary Hepatocytes
(A) Hepatocytes from WT, AMPKa1/, and
AMPKa2/ mice were treated with the indicated
concentrations of C13 and labeled with [1-14C]
acetate for 3 hr. Rates of fatty acid and sterol
synthesis were estimated from incorporation into
saponifiable (upper graphs) and nonsaponifiable
(lower graphs) lipids. Results are expressed as
percentage WT vehicle and represent the mean ±
SD for three independent experiments.
(B) Mouse hepatocytes were incubated with the
indicated concentrations of C13 for 3 hr, and
lysates were analyzed using western blotting with
the indicated antibodies.
plexes insensitive to AMP. The side chain
of Arg531 interacts with the phosphate
group of AMP bound in site 3, so this sug-
gests that C2 binds in that site. These re-
sults suggest that C2 uses the same bind-
ing sites on the AMPKg subunit as AMP
and ATP, most likely sites 1 and 3 (Xiao
et al., 2011). This is also supported by
our findings that (1) the effect of C2 on
a1 complexes was not additive with that
of AMP, that (2) C2 reduced the activation
of a2 complexes by AMP, and that (3) the
activation of an a1b1g1 complex by C2
was antagonized by ADP, which also
binds to sites 1 and 3. C2 had no effect
on the activity of full-length isolated a
subunits, unlike nonnucleotide com-
pounds reported to function by disrupting
the interaction between the catalytic sub-
unit and the autoinhibitory domain (Li
et al., 2013; Pang et al., 2008). In addition, C2 does not produce
the biphasic allosteric activation of AMPK by AMP caused
by competition of high concentrations of AMP with ATP at the
catalytic site (Gowans et al., 2013).
Assuming that C2 binds exclusively to the nucleotide sites on
the g subunit, its ability to discriminate between a1 and a2 com-
plexes was unexpected, so we sought to identify themechanism
underlying this. The g subunit has four potential nucleotide-bind-
ing sites, but one (site 2) is unused, leaving three (sites 1, 3, and 4)
where adenine nucleotides can bind. In the structure for an
active a1b2g1 complex (Xiao et al., 2011), the a linker that con-
nects the AID and CTD wraps around one face of the g subunit,
contacting AMP bound in site 3 (Xiao et al., 2011). Interestingly,
there is relatively low conservation of sequence between a1 and
a2 within the a linker, and this has been exploited to generate
isoform-specific antibodies. Based on the original model (Xiao
et al., 2011), it was proposed that a region in the a linker termed
the a hook (R384-N393 in rat a1, P54645) interacted with AMP in
site 3. We therefore hypothesized that differences in the interac-
tion between the a1 and a2 hook and C2 bound in site 3might be
responsible for the ability of C2 to discriminate between a sub-
unit isoforms. However, substitution of the a hook region in a
complex between an a2/a1 chimera and b1 and g1 had no
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impact on the sensitivity to C2, although replacement of a more
extended region of the a linker fully restored sensitivity to the
allosteric activation and protection of Thr172 phosphorylation
by C2. The likely explanation for this anomaly came when it
was suggested (Chen et al., 2013; Xin et al., 2013) that the orig-
inal assignment of amino acid sequence to electron density in
the a hook region (Xiao et al., 2011) may have been incorrect.
Very recently this change has been accepted by the original au-
thors (Xiao et al., 2013), resulting in the replacement of the orig-
inal atomic coordinates in the Protein Data Bank (PDB ID 2Y94)
with a revised version (4CFH). This model suggests that the re-
gion from 343 to 353 in human a1 (Q13131), termed a-regulatory
subunit-interacting motif-1 (a-RIM1), associates with the unoc-
cupied site 2, whereas the region from 369 to 379 (a-RIM2) asso-
ciates with AMP bound in site 3 (Xin et al., 2013). Using our
chimeric a2/a1 loop complex, in which a more extended region
of the a1 linker (including a-RIM2 and the former a hook
sequence, but excluding a-RIM1) was used to replace the equiv-
alent region in an a2b1g1 complex, we observed full allosteric
activation and protection against Thr172 dephosphorylation.
These results support the revised model and also strongly sug-
gest that the different sequences of a1 and a2 in the a-RIM2 re-
gion cause differing interactions with C2 bound in site 3, leading
to the selectivity of C2/C13 for a1 versus a2 complexes. Our re-
sults also support the view that C2 binds at site 3 and that this
affects both allosteric activation and protection against the
dephosphorylation of Thr172. Xiao et al. (2011) previously
argued that site 1 was the important binding site for allosteric
activation by AMP,whereasChen et al. (2012) provided evidence
in favor of the importance of sites 3 and 4. Our results support an
important role for site 3 while not excluding additional roles of
sites 1 and 4.
In summary, we report the detailed characterization and po-
tential mechanism of action of an AMP-mimetic but a1-selective
AMPK activator that, unlike AICAR or ZMP, is completely selec-
tive for AMPK compared to other AMP-regulated or -metabo-
lizing enzymes. Although the preference for a1-containing
complexes may limit its use for some indications, this shows
that it is possible to develop a isoform-specific activators, along
with the b isoform-selective activators typified by A769662.
Recently, Scott et al. (2014b) reported a small-molecule activator
of AMPK (JJO1) that activated AMPKa1- and AMPKa2-contain-
ing complexes independently of the b subunit CBD but was inac-
tive with g3. A more complete understanding of the mechanism
by which small molecules activate AMPK may facilitate the
design of additional AMPK activators that could be used to treat
patients with metabolic disorders.
SIGNIFICANCE
AMP-activated protein kinase (AMPK) is a central energy
sensor and regulator of metabolic homeostasis. The activa-
tion of AMPKprovides desirable therapeutic effects inmeta-
bolic disorders such as type 2 diabetes. However, there is
currently no direct AMPK activator available for the treat-
ment of metabolic disorders. Only a handful of small mole-
cules have been reported to directly stimulate AMPK with
no defined mechanism of action mode elaborated except
for A769662, which stimulates b1-containing complexes.
We performed an extensive characterization of a recently
identified AMPK activator, a nucleotide mimetic, termed
Compound 2 (C2) and its prodrug C13. We observed that
C2 stimulates AMPK at least 20-fold more potently than
A769662 in cell-free assays, with absolute specificity over
other AMP-regulated or -metabolizing enzymes. We also
found that C2 stimulates AMPK by mimicking both effects
of AMP, allosteric activation and inhibition of dephos-
phorylation via protein phosphatase (PP2C). Strikingly, we
identified that C2 preferentially stimulates a1-containing
complexes and identified a sequence located in the
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Figure 7. C13 Activates Both b1 and b2 Complexes in Mouse
Hepatocytes
(A) Hepatocytes from WT, AMPKb1/, and AMPKb2/ mice were incubated
with the indicated concentrations of C13 for 1 hr. A769662 (100 mM) was
included as a positive control. Lysates were analyzed using western blotting
with the indicated antibodies.
(B) Mouse hepatocytes from the indicated genotypes were treated with
the indicated concentrations of C13 and labeled with [3H]acetate for 4 hr.
Lipogenesis was estimated from the incorporation of acetate into total lipids.
Results are expressed as the mean acetate incorporated in micromoles per
gram-hour ± SD.
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C-terminal region of a1, outside the catalytic domain, which
confers this specificity. The selectivity of the compound for
a1 complexes in cell-free assays was consistent with the
ability of the cell-permeable prodrug C13 to potently inhibit
hepatic lipogenesis in primary mouse hepatocytes, which
was reversed in AMPKa1-deficient hepatocytes. This dem-
onstrates that it is possible to develop isoform-selective
compounds outside the b subunit carbohydrate-binding-
module-dependent compounds, typified by A769662. A
more complete understanding of the mechanism by which
small molecules activate AMPK may also facilitate the
design of novel AMPK activators that could be used to treat
patients with metabolic disorders.
EXPERIMENTAL PROCEDURES
Animals
Animal studies were approved by the University of Dundee ethics committee
and performed under a UKHomeOffice project license. All animals weremain-
tained on a 12/12 hr light/dark cycle and had free access to standard chow
and water. AMPKa1/, AMPKa2/ and liver AMPK-null (AMPKa1/ and
liver-specific AMPKa2/) mice were generated and bred, as previously
described (Foretz et al., 2010; Jørgensen et al., 2004; Viollet et al., 2003). Ex-
periments using AMPKa-null models were performed under the approval of
the ethics committee from University Paris Descartes (no. CEEA34.BV.157.12)
and a French authorization to experiment on vertebrates (no.75-886) in accor-
dance with the European guidelines. AMPKb1/ and AMPKb2/ mice were
generated as previously described (Dzamko et al., 2010; Steinberg et al.,
2010), and experiments were conducted under the approval of the McMaster
University animal ethics research board.
AMPK Assay
AMPK phosphotransferase activity was assayed in reactions (50 ml) containing
50mMHEPES, pH 7.4, 10 mMMgCl2, 0.1 mMEGTA, 1 mMDTT, 0.01%BRIJ-
35, 100 mM [g-32P]ATP (250 CPM,pmol1) and 200 mM AMARA (AMARAA
SAAALARRR). Reactions were started by the addition of AMPK (5 mU), incu-
bated for 20 min at 30C and quenched by spotting onto P81 and immersion
in 75mMH3PO4.Washed filters were dried and [
32P] incorporation determined
by Cherenkov counting. AMPK activity in cell extracts was determined by
immunoprecipitationwith AMPKa1 or AMPKa2 antibodies from 50 mgmaterial,
as previously described (Hunter et al., 2011). Results are expressed as pico-
moles Pi incorporated per minute-milligram or the fold increase in activity
compared to controls in the absence of the compound and were fitted to the
following equation:
v = vo +
(
ðvmax  voÞ½Ah
Kha + ½Ah
)
;
where v is the velocity, vo is the velocity in the absence of compound, [A] is the
concentration of activator, Ka is the concentration of activator that increases
velocity to 50% maximal stimulated activity, and h is the Hill coefficient.
Phosphatase Protection Assay
AMPKa1b1g1 or a2b1g1 was dephosphorylated in vitro with PP2Ca in 50 mM
HEPES pH 7.4, 10 mMMgCl2, 0.1 mM EGTA, 0.03% BRIJ-35, 1 mM DTT, and
the indicatedcompounds for 15minat30C.Mg2+wasomitted fromthenegative
control. Reactionswere terminated by20-fold dilution and storage on ice. AMPK
activity was assayed under standard conditions in the presence of saturating
AMP (200 mM). The results are expressed as percentage activity of the negative
control. In control experiments, PP2Caactivitywasdetermined in reactions con-
taining 50mMTESpH7.4, 0.1mMEGTA,25mMMgCl2, 0.01%BRIJ-35, 0.02%
(v/v) 2-mercaptoethanol, and100mMEFLR(pT)SCGS (168–176AMPKa2). Liber-
ated phosphate was determined using malachite green (Baykov et al., 1988).
Lipid Synthesis
Lipid synthesis was determined by labeling adherent cultures of primary hepa-
tocyteswith [1-14C]acetate. After overnight culture, hepatocytes (53 105) were
washed with warm PBS and allowed to rest for 3 hr in fresh M199. Cells were
treated with vehicle (0.1% DMSO) or the indicated compounds and labeled
with 1 mCi,mmol1 [1-14C]acetate for 3 hr. Cells were washed with ice-cold
PBS, gently scraped into 0.5 ml PBS and saponified in methanolic KOH at
80C for 1 hr. Nonsaponifiable and saponifiable lipids were extracted with pe-
troleum ether before and after acidification with HCl. Lipid fractions were
washed with 5%HAc, dried using N2, and dissolved in scintillant for the deter-
mination of [14C] incorporation. Lipogenesis in hepatocytes from AMPKb1/b2-
KO mice was determined in media containing [3H]acetate (0.2 mCi,mmol1).
After 4 hr labeling, total lipids were extracted using the method of Bligh and
Dyer (1959), and incorporated [3H] was determined by scintillation counting.
The results are expressed asmicromoles acetate incorporated per gram-hour.
Fatty Acid Esterification
Fatty acid esterification was determined by labeling primary hepatocytes with
[9,10-3H(N)]palmitate. After overnight culture, hepatocytes (5 3 105) were
washed with warm PBS and allowed to rest for 3 hr in fresh M199 containing
0.5mMcarnitine. Cells were treatedwith vehicle (0.1%DMSO) or the indicated
compounds for 30 min and labeled with 1 mCi,mmol1 [9,10-3H(N)]palmitic
acid (0.5 mM palmitic acid, 1.34% BSA = 2.5:1 C16:0/BSA) for an additional
1 hr. Cells were washed with ice-cold PBS, lipids extracted using the method
of Bligh and Dyer, and neutral lipids were resolved on TLC plates (Partisil K6)
in 70:30:1 petroleum ether:diethyl ether:acetic acid. Lipids were stained with
iodine vapor and triglyceride eluted from TLC scrapings with 1:1 ethanol:Triton
X-100, and the incorporation of [3H] was determined by scintillation counting.
SUPPLEMENTAL INFORMATION
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